Moreover, bladder cancer patients rich in CDH12 had excellent responses to immune checkpoint therapy, providing strong evidence for the design of biomarker guided clinical trials.[112] In addition, spatial metabolomics and spatial proteomics combined with SRT analysis elucidate the tumor‐host cell interaction, and well reveal the spatio‐temporal alterations of transcriptional heterogeneity and regional hypoxia metabolism in glioblastoma (GBM). This evidence concerns the gene CDH12 and urinary bladder cancer.